resm glp 1 postbiotic Resbiotic Expands Global Footprint with Strategic Distribution Agreement in Mexico GLP-1 Postbiotic Supplements: Resbiotic's resM

GLP-1 receptor agonists (GLP-1 RAs), already established in the management of type 2 diabetes mellitus and obesity, have emerged as promising candidates for the treatment of nonalcoholic steatohepatitis (NASH), owing to their broad metabolic and hepatoprotective effects

Hims & Hers has been slower to enter the weight management space compared to its peers

Thats slower than the 15% body weight loss seen with standard semaglutide in the STEP trials

Adequate hydration represents an important intervention

The sheer volume of patients MedVi has treated gives it a data advantage that newer platforms simply can't match

This is a significant advancement since managing heart failure with preserved ejection fraction has been challenging with limited treatment options